Jasper Therapeutics, Inc. (JSPR)

Market Cap	59.64M
Revenue (ttm)	n/a
Net Income (ttm)	-71.27M
Shares Out	15.02M
EPS (ttm)	-4.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	85,842
Open	4.070
Previous Close	3.920
Day's Range	3.940 - 4.070
52-Week Range	3.130 - 26.840
Beta	2.56
Analysts	Strong Buy
Price Target	62.50 (+1,474.31%)
Earnings Date	May 13, 2025

About JSPR

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 64
• Stock Exchange: NASDAQ
• Ticker Symbol: JSPR
• Website: https://jaspertx.com

Analyst Forecast

According to 10 analysts, the average rating for JSPR stock is "Strong Buy." The 12-month stock price forecast is $62.5, which is an increase of 1,474.31% from the latest price.

Price Target

$62.5

(1,474.31% upside)

Analyst Consensus: Strong Buy